Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Learn more about HealthTree
Video

Pivekimab Sunirine Approval for #BPDCN: A New CD123-Targeted Treatment | EHA 2026

Posted by
HealthTree Logo HealthTree
• June 29, 2026

Description

Dr. Naveen Pemmaraju shares breaking news about Pivekimab sunirine (PVEK) approval for BPDCN - the second CD123-targeted drug ever approved. Recorded at E-Hawa 2026 in Stockholm, Sweden.

Topics Covered:
- What is BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)?
- CD123 as a treatment target
- First drug: Tagraxofusp (TAG)
- New approval: Pivekimab sunirine (PVEK) - monotherapy, single-agent treatment
- Efficacy: High remission rates and stem cell transplant eligibility
- Important side effects: Liver function monitoring, VOD/SOS, peripheral edema
- Future: Combination therapy opportunities in clinical trials

Pivekimab sunirine can be given every 3 weeks as an outpatient treatment for relapsed/refractory or frontline BPDCN.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction & Conference Context
0:27 What is BPDCN?
0:49 First CD123 Drug: Tagraxofusp (TAG)
0:53 Breaking News: PVEK Approval
1:16 PVEK: How It Works & Benefits
1:39 Important Side Effects to Monitor
2:22 Future: Combination Therapy Opportunities

#BPDCN #CD123 #RareCancer #Leukemia #ClinicalTrial

Related Content